These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 15256455)
1. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Youn CK; Kim MH; Cho HJ; Kim HB; Chang IY; Chung MH; You HJ Cancer Res; 2004 Jul; 64(14):4849-57. PubMed ID: 15256455 [TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979 [TBL] [Abstract][Full Text] [Related]
3. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453 [TBL] [Abstract][Full Text] [Related]
4. Regulation of DNA repair gene expression in human cancer cell lines. McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315 [TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380 [TBL] [Abstract][Full Text] [Related]
6. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer]. Liu GY; Qu QX; Mi RR; Qi J Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932 [TBL] [Abstract][Full Text] [Related]
7. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. Stordal B; Davey R Cancer Chemother Pharmacol; 2009 Mar; 63(4):661-72. PubMed ID: 18575867 [TBL] [Abstract][Full Text] [Related]
8. MZF1 possesses a repressively regulatory function in ERCC1 expression. Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580 [TBL] [Abstract][Full Text] [Related]
9. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1). Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Li W; Melton DW Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734 [TBL] [Abstract][Full Text] [Related]
11. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Andrieux LO; Fautrel A; Bessard A; Guillouzo A; Baffet G; Langouët S Cancer Res; 2007 Mar; 67(5):2114-23. PubMed ID: 17332341 [TBL] [Abstract][Full Text] [Related]
12. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival. Xin H; Geng Y; Pramanik R; Choubey D J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788 [TBL] [Abstract][Full Text] [Related]
13. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Cummings M; Higginbottom K; McGurk CJ; Wong OG; Köberle B; Oliver RT; Masters JR Biochem Pharmacol; 2006 Jul; 72(2):166-75. PubMed ID: 16756962 [TBL] [Abstract][Full Text] [Related]
14. MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. Yacoub A; Park JS; Qiao L; Dent P; Hagan MP Int J Radiat Biol; 2001 Oct; 77(10):1067-78. PubMed ID: 11682011 [TBL] [Abstract][Full Text] [Related]
15. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Yu D; Zhang X; Liu J; Yuan P; Tan W; Guo Y; Sun T; Zhao D; Yang M; Liu J; Xu B; Lin D Clin Cancer Res; 2008 May; 14(9):2878-86. PubMed ID: 18451256 [TBL] [Abstract][Full Text] [Related]
16. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035 [TBL] [Abstract][Full Text] [Related]
17. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192 [TBL] [Abstract][Full Text] [Related]
18. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Olaussen KA; Mountzios G; Soria JC Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174 [TBL] [Abstract][Full Text] [Related]
19. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line. Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987 [TBL] [Abstract][Full Text] [Related]